Search

Fate Therapeutics Inc

Отворен

СекторЗдравеопазване

2.52 -1.56

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.5

Максимум

2.59

Ключови измерители

By Trading Economics

Приходи

1.1M

-30M

Продажби

783K

2.1M

EPS

-0.25

Марж на печалбата

-1,448.559

Служители

161

EBITDA

-2.3M

-31M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+160.7% upside

Дивиденти

By Acuity

Следващи печалби

12.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-29M

292M

Предишно отваряне

4.08

Предишно затваряне

2.52

Настроения в новините

By Acuity

100%

0%

325 / 340 Класиране в Healthcare

Fate Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.08.2026 г., 19:46 ч. UTC

Fate Therapeutics shares are higher Wednesday, despite a pullback from earlier gains. No specific news was identified to explain the price movement.

24.08.2026 г., 19:46 ч. UTC

Fate Therapeutics Inc is trading higher amid broader market dynamics influenced by rising oil prices and geopolitical tensions, though no specific news was identified.

22.08.2026 г., 00:02 ч. UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting broader market gains following recent pressures from rising crude oil prices and bond yields.

20.08.2026 г., 20:06 ч. UTC

Correlated Moves

Fate Therapeutics Inc is declining today, mirroring a broader market drop. The stock remains below its 20-day moving average and near its one-month low.

19.08.2026 г., 19:26 ч. UTC

Correlated Moves

Fate Therapeutics Inc shares are higher, supported by a significant rise in the ARK Genomic Revolution ETF during Wednesday's session.

14.08.2026 г., 19:26 ч. UTC

Event
Social Media
News

Fate Therapeutics has begun its Phase 2 RECLAIM-LN trial for FT819, targeting lupus nephritis. Shares are higher during Friday's session.

13.08.2026 г., 23:36 ч. UTC

Fate Therapeutics shares are higher in after-market hours, reflecting a recovery from earlier declines amid broader market optimism regarding the Federal Reserve's interest rate policy.

12.08.2026 г., 21:02 ч. UTC

Fate Therapeutics Inc. is gaining in after-market trading, rebounding from three consecutive sessions of declines. The price remains above the 20-day moving average.

7.08.2026 г., 20:03 ч. UTC

Fate Therapeutics shares are higher, reaching a session high amid rising U.S. Treasury yields and a weakening U.S. Dollar Index. No specific news identified.

6.08.2026 г., 19:26 ч. UTC

Correlated Moves

Fate Therapeutics Inc shares are lower today, reflecting broader market trends and a decline in the Russell 2000 Index amid ongoing inflation concerns.

5.08.2026 г., 19:56 ч. UTC

Fate Therapeutics shares are higher amid positive market sentiment and falling oil prices, despite some volatility during Wednesday's trading session.

4.08.2026 г., 20:07 ч. UTC

News
Correlated Moves

Fate Therapeutics is gaining as it announces employee inducement awards, including stock options at $2.45 per share. Shares rebounded after an earlier pullback.

3.08.2026 г., 23:01 ч. UTC

News

Fate Therapeutics Inc. shares are lower in after-market trading, despite stronger growth in the manufacturing sector and recent employee inducement awards.

29.07.2026 г., 19:19 ч. UTC

Fate Therapeutics is trading higher amid positive market momentum ahead of the Federal Reserve's monetary policy announcement, despite lingering inflation concerns.

28.07.2026 г., 16:06 ч. UTC

Fate Therapeutics shares are lower amid broader market weakness and investor caution ahead of key earnings reports and the Federal Reserve's interest rate decision.

27.07.2026 г., 21:02 ч. UTC

Fate Therapeutics shares are higher in after-market hours, despite no specific news. Broader market sentiment is improving with rising European equity indices.

24.07.2026 г., 19:07 ч. UTC

Correlated Moves

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

23.07.2026 г., 21:11 ч. UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

22.07.2026 г., 23:46 ч. UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

20.07.2026 г., 18:26 ч. UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Сравнение с други в отрасъла

Ценова промяна

Fate Therapeutics Inc Прогноза

Ценова цел

By TipRanks

160.7% нагоре

12-месечна прогноза

Среден 6.7 USD  160.7%

Висок 8 USD

Нисък 3.5 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Fate Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

7 ratings

4

Купи

3

Задържане

0

Продай

Настроение

By Acuity

325 / 340 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat